Summary Semaglutide is a powerful medication that offers promising results in weight loss
Apitegromab represents a clear advancement over ACE-031 in myostatin pathway therapeutics
Patients with favorable genetic predictors often achieve goals at lower doses, maximizing both efficacy and affordability
These treatments work best as part of a broader health plan
is supported by the Swedish Research Council (grant numbers 2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (grant numbers AF-930351, AF-939721, AF-968270 and AF-994551), Hjrnfonden, Sweden (grant numbers ALZ2022-0006, FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant numbers ALFGBG-965240 and ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (grant number JPND2019-466-236), the Alzheimers Association 2021 Zenith Award (grant number ZEN-21-848495), the Alzheimers Association 2022-2025 Grant (grant number SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rnstrms Stiftelse, Stockholm, Sweden and an anonymous filantropist and donor
